Clearside Biomedical, Inc. (CLSD)
Stock Price:
$1.76 USD
-0.03 (-1.68%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
78.97M |
| Revenue (ttm) |
6.23M |
| Net Income (ttm) |
-18.28M |
| Shares Out |
54.31M |
| EPS (ttm) |
-0.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$1.76 |
| Previous Close |
$1.79 |
| Change ($) |
-0.03 |
| Change (%) |
-1.68% |
| Day's Open |
1.78 |
| Day's Range |
1.71 - 1.79 |
| Day's Volume |
125,242 |
| 52-Week Range |
0.56 - 4.13 |
More Stats
| Market Cap |
78.97M |
| Enterprise Value |
64.06M |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
54.31M |
| Float |
29.61M |
| EPS (basic) |
-0.45 |
| EPS (diluted) |
-0.45 |
| FCF / Share |
-0.39 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.57M |
| Short Ratio |
5.61 |
| Short % of Float |
3.79% |
| Beta |
0.99 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
12.69 |
| PB Ratio |
9.57 |
| Revenue |
6.23M |
| Operating Income |
-17.91M |
| Net Income |
-18.28M |
| Free Cash Flow |
-17.28M |
| Net Cash |
14.91M |
| Net Cash / Share |
0.33 |
| Gross Margin |
34.91% |
| Operating Margin |
-287.69% |
| Profit Margin |
-293.60% |
| FCF Margin |
-277.59% |
| ROA |
-35.62% |
| ROE |
-137.78% |
| ROIC |
-1,151.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
3 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$5.75*
(226.70% upside)
Low
3.00
Current: $1.76
High
8.00
Target: 5.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 2.17 | 0.03 | 0.35 | 0.52 | - | - |
| Revenue Growth | 7143.33% | -91.3% | -33.65% | - | - | - |
| Gross Profit | 2.17 | 0.03 | 0.35 | 0.52 | - | - |
| Operating Income | -30.30 | -82.95 | -58.41 | -25.20 | -17.64 | -10.19 |
| Net Income | -30.77 | -82.82 | -58.98 | -25.88 | -17.64 | -10.19 |
| Shares Outstanding | 38.17 | 30.73 | 25.31 | 13.11 | 2.34 | 1.74 |
| Earnings Per Share | -0.81 | -2.69 | -2.33 | -1.97 | -7.54 | -5.86 |
| Operating Cash Flow | -27.07 | -79.20 | -51.08 | -22.71 | -13.90 | -9.12 |
| Capital Expenditures | -0.03 | -0.09 | -0.31 | - | -0.03 | -0.14 |
| Free Cash Flow | -27.09 | -79.29 | -51.39 | -22.71 | -13.93 | -9.26 |
| Cash & Equivalents | 22.96 | 41.24 | 38.00 | 83.99 | 20.28 | 0.00 |
| Total Debt | 6.41 | 9.98 | 8.01 | 7.59 | 5.98 | - |
| Net Cash / Debt | 16.55 | 31.26 | 29.99 | 76.41 | 14.31 | 0.00 |
| Assets | 26.78 | 44.12 | 40.49 | 84.81 | 21.06 | - |
| Liabilities | 15.62 | 20.50 | 19.08 | 13.15 | 10.40 | - |
| Book Value | 11.16 | 23.62 | 21.42 | 71.66 | -36.66 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Clearside Biomedical, Inc. |
| Country |
United States |
| Employees |
33 |
| CEO |
George M. Lasezkay |
Stock Information
| Ticker Symbol |
CLSD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLSD |
| IPO Date |
June 2, 2016 |
Description
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.